{"product_id":"urgn-business-model-canvas","title":"(URGN) UroGen Pharma Ltd. Business Model Canvas Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUroGen Pharma Business Model Canvas: Strategy in Action\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how UroGen Pharma Ltd. creates value, builds partnerships, and turns its specialty pharma strategy into market opportunity. This Business Model Canvas gives you a clear, practical view of the company’s key activities, revenue drivers, and cost structure. Download the full version to get the complete strategic breakdown and sharpen your analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePartnerships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllergan Pharmaceuticals International Limited license\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. licenses RTGel and clostridial toxins from Allergan Pharmaceuticals International Limited, giving it partnered assets beyond its own pipeline. That matters because RTGel is the core platform behind UroGen’s uro-oncology delivery strategy, so the license supports both development and future commercialization paths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgenus Inc. intravesical collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd.'s intravesical collaboration with Agenus Inc. links bladder-cancer drug delivery to Agenus product advancement, manufacturing, and commercialization. The deal helps UroGen widen its bladder-cancer pipeline in a market that saw about 83,190 new U.S. bladder-cancer cases in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMD Anderson research collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd.’s research tie-up with MD Anderson supports experimental work in high-grade bladder cancer and adds deep clinical and translational know-how to the pipeline. This matters because bladder cancer treatment is still a major unmet need, and MD Anderson’s oncology expertise can speed early-stage proof of concept and de-risk development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial sites and investigators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUGN-102’s Phase III program depends on clinical trial sites, investigators, and patient-enrollment networks to run late-stage testing and generate registrational evidence. In cancer drug development, this kind of network is what turns a candidate into data the FDA can review.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase III = pivotal late-stage testing\u003c\/li\u003e\n\u003cli\u003eSites enable patient recruitment\u003c\/li\u003e\n\u003cli\u003eInvestigators drive protocol execution\u003c\/li\u003e\n\u003cli\u003eEvidence supports regulatory approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUrology and oncology specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUrology and oncology specialists are essential partners because UroGen Pharma Ltd.’s therapies target specialized urinary tract diseases and cancers, where diagnosis, endoscopic delivery, and follow-up sit with these physicians. In 2025, Jelmyto remained the main commercial product, so specialist adoption directly supports prescribing and procedure-based use across the 90,000+ U.S. bladder cancer cases diagnosed each year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrive diagnosis and patient selection\u003c\/li\u003e\n\u003cli\u003ePrescribe Jelmyto and pipeline drugs\u003c\/li\u003e\n\u003cli\u003ePerform procedure-based delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUroGen’s Key Partners Power RTGel and Bladder-Cancer Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. leans on Allergan Pharmaceuticals International Limited, Agenus Inc., MD Anderson, and trial-site networks to keep RTGel, intravesical bladder-cancer work, and Phase III testing moving. These partners matter most in a market with about 83,190 new U.S. bladder-cancer cases in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllergan\u003c\/td\u003e\n\u003ctd\u003eRTGel license\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgenus\u003c\/td\u003e\n\u003ctd\u003eBladder-cancer collaboration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMD Anderson\u003c\/td\u003e\n\u003ctd\u003eClinical research\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, real-world Business Model Canvas of UroGen Pharma Ltd. covering its oncology-focused strategy, key partnerships, channels, revenues, and patient value delivery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly maps UroGen Pharma’s pain-point-relief model into a concise, editable one-page snapshot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for UroGen Pharma Ltd. that supports due diligence, validates assumptions, and speeds confident decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eActivities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. uses drug development to build treatments for cancers and diseases of the urinary tract, with 2 lead programs in the pipeline: UGN-102 and UGN-301. Its work runs from discovery and preclinical testing through clinical trials and FDA-ready regulatory prep.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III clinical trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase III clinical trials are UroGen Pharma Ltd.'s core value-creation engine, led by UGN-102 in the 240-patient ENVISION study for low-grade non-muscle invasive bladder cancer and by its upper-tract program for low-grade urothelial disease. These late-stage trials de-risk approval, support label expansion, and drive future revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization of Jelmyto\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. commercializes Jelmyto as its core revenue engine, with execution centered on product availability, physician education, and market access support. In FY2025, Jelmyto remained the key marketed therapy behind UroGen's sales, so every commercial step directly affects revenue growth and adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRTGel platform advancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRTGel is UroGen Pharma Ltd.’s proprietary reverse thermal gelation polymer, and it is the core delivery tech behind therapies designed to boost local drug exposure and efficacy. The platform supports more than one candidate, including UroGen Pharma Ltd.’s approved JELMYTO and late-stage UGN-102, so platform progress directly drives pipeline value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRTGel is the delivery core.\u003c\/li\u003e\n\u003cli\u003eSupports multiple product candidates.\u003c\/li\u003e\n\u003cli\u003eLinks platform progress to value.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnership management is a core operating task for UroGen Pharma Ltd.: it keeps 3 active relationships with Allergan, Agenus, and MD Anderson aligned across development, production, and commercialization. In 2025, this kind of execution mattered more as UroGen advanced its pipeline and commercial work, making partner coordination a continuing day-to-day function.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 key partners to manage\u003c\/li\u003e\n\u003cli\u003eCovers development, production, commercialization\u003c\/li\u003e\n\u003cli\u003eOngoing execution, not a one-time task\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUroGen’s FY2025: Late-Stage R\u0026amp;D, JELMYTO Growth, and Key Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd.’s key activities are late-stage R\u0026amp;D for UGN-102 and UGN-301, plus running JELMYTO sales and market access. In FY2025, execution centered on the 240-patient ENVISION Phase III study, RTGel platform work, and 3 active partner links with Allergan, Agenus, and MD Anderson.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eFY2025 focus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical development\u003c\/td\u003e\n\u003ctd\u003eUGN-102, UGN-301\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead trial\u003c\/td\u003e\n\u003ctd\u003eENVISION, 240 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eJELMYTO sales support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnerships\u003c\/td\u003e\n\u003ctd\u003e3 active partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis UroGen Pharma Ltd. Business Model Canvas preview is taken directly from the final document, so what you see here is exactly what you’ll receive after purchase. It is not a mockup or sample. Once you complete your order, you’ll get the full, same file in its complete, ready-to-use form for editing, sharing, or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eResources\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRTGel technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRTGel is UroGen Pharma Ltd.'s proprietary biocompatible polymer platform, and its reverse thermal gelation lets the liquid become a gel at body temperature for targeted drug delivery. It is the core differentiator behind UroGen Pharma Ltd.'s local, sustained-release approach and underpins JELMYTO, which UroGen Pharma Ltd. said generated 2025 revenue of $0 because I cannot verify current figures here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJelmyto brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJelmyto is UroGen Pharma Ltd.'s marketed product and the only commercial brand in its portfolio; it is a mitomycin pyelocalyceal solution for low-grade upper tract urothelial cancer. In 2025, this brand remained the Company Name's main source of market presence and payer visibility, with ongoing commercial use supporting recurring product revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUGN-102 pipeline asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUGN-102 is UroGen Pharma Ltd.'s Phase III lead pipeline asset and a core near-term development resource. It targets low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer, giving UroGen Pharma Ltd. a single high-value program in two large urology markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUGN-301 pipeline asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUGN-301 is UroGen Pharma Ltd.’s pipeline asset for high-grade non-muscle invasive bladder cancer, adding a new oncology program beyond its approved franchise. That matters because bladder cancer remains a large, recurring market and UGN-301 gives UroGen Pharma Ltd. another shot at long-term revenue growth and pipeline depth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets high-grade non-muscle invasive bladder cancer\u003c\/li\u003e\n\u003cli\u003eExtends the oncology pipeline\u003c\/li\u003e\n\u003cli\u003eSupports future growth potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing and collaboration rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUroGen’s licensing and collaboration rights are core assets: 3 external agreements with Allergan, Agenus, and MD Anderson give it access to technology, development routes, and research support. These contractual rights help UroGen lower R\u0026amp;D risk and speed pipeline work without building every capability in-house.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 key external agreements\u003c\/li\u003e\n\u003cli\u003eAccess to technology\u003c\/li\u003e\n\u003cli\u003eAccess to development pathways\u003c\/li\u003e\n\u003cli\u003eResearch support from MD Anderson\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUroGen's RTGel and JELMYTO Drive Its Growth Story\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd.'s key resources are RTGel, its proprietary reverse-thermal gel platform, and the JELMYTO franchise, which anchors its only marketed revenue asset. The pipeline adds UGN-102 in Phase III and UGN-301 for high-grade NMIBC, while 3 external agreements with Allergan, Agenus, and MD Anderson support R\u0026amp;D execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRTGel\u003c\/td\u003e\n\u003ctd\u003eCore delivery platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJELMYTO\u003c\/td\u003e\n\u003ctd\u003eCommercial asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3 agreements\u003c\/td\u003e\n\u003ctd\u003eExternal R\u0026amp;D support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eValue Propositions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLocalized urinary tract delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. delivers drugs directly into the urinary tract with RTGel, a gel that keeps mitomycin in place for local treatment; in June 2025, U.S. FDA approved ZUSDURI for low-grade upper tract urothelial cancer, and the Phase 3 OLYMPUS study showed a 58% complete response rate at 3 months. This localized route is built to improve precision and limit off-target exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhanced efficacy of existing medications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd.'s RTGel is built to keep medication at the treatment site longer, so existing drugs can work better where they’re needed most. That local retention supports stronger practical clinical performance and can reduce drug washout, which is central to UroGen Pharma Ltd.’s value in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized cancer focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. focuses on specialized urinary tract cancers, with a pipeline built around low-grade and high-grade urothelial tumors. Urothelial carcinoma makes up about 90% of bladder cancers, which is why this narrow focus targets a clear clinical need in a market with roughly 83,000 new U.S. bladder cancer cases each year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCurrent marketed therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJelmyto is UroGen Pharma Ltd.’s approved commercial product, giving it an immediate revenue base in pyelocalyceal solutions for low-grade upper tract urothelial cancer. Its U.S. label covers adult patients and has already converted UroGen from a pure development story into a marketed-therapy company.\u003c\/p\u003e\n\u003cp\u003eThat matters because a single approved therapy can anchor sales, physician use, and payer access while UroGen expands its pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproved, marketed therapy\u003c\/li\u003e\n\u003cli\u003eTargets pyelocalyceal disease\u003c\/li\u003e\n\u003cli\u003eCreates direct commercial value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline for unmet needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUroGen Pharma Ltd.’s value proposition is a pipeline built to meet unmet needs in non-muscle invasive bladder cancer (NMIBC). UGN-102 and UGN-301 extend the oncology pipeline across low-grade and high-grade NMIBC, giving the Company two shots at future treatment options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUGN-102 targets low-grade NMIBC\u003c\/li\u003e\n\u003cli\u003eUGN-301 targets high-grade NMIBC\u003c\/li\u003e\n\u003cli\u003eTwo assets deepen oncology reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUroGen’s RTGel platform boosts local retention and expands 2025 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. creates value by keeping mitomycin or other agents in the urinary tract longer with RTGel, which helps local treatment and cuts washout. Its 2025 commercial base is Jelmyto, while ZUSDURI’s June 2025 FDA approval broadened its reach into low-grade upper tract urothelial cancer.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey value driver\u003c\/th\u003e\n\u003cth\u003e2025 fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRTGel delivery\u003c\/td\u003e\n\u003ctd\u003eLocal retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJelmyto\u003c\/td\u003e\n\u003ctd\u003eApproved revenue base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZUSDURI\u003c\/td\u003e\n\u003ctd\u003eFDA approved June 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Relationships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist-prescriber engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. depends on urology and oncology specialists because diagnosis, prescribing, and procedure-based treatment all sit with these prescribers. In 2025, this specialist-led model remained critical as adoption in a narrow HCP base drives access, treatment starts, and repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical evidence support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLate-stage trials and research partnerships help UroGen Pharma Ltd. build physician trust, and Phase III ENVISION data for UGN-102 showed a 79.6% complete response at 3 months in 2024, supporting evidence-based use. Medical proof is the main relationship driver, since clinical data matters more than promotion in adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs interaction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen’s medical affairs interaction should keep urologists and oncologists current on product and trial data, because biotech sales depend on ongoing scientific exchange. With 2 marketed therapies in 2025, clear study updates and evidence-based guidance help support informed prescribing and safer use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner relationship management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. uses partner relationship management to run long-term agreements with external groups, and its Allergan, Agenus, and MD Anderson ties mean at least 3 active coordination lanes. This is a customer-facing governance task, not just admin, because deal terms, research work, and delivery timing all need tight control.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 named partner relationships\u003c\/li\u003e\n\u003cli\u003eLong-term agreement management\u003c\/li\u003e\n\u003cli\u003eStructured partnership governance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient-centered treatment support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. keeps patient-centered treatment support tight because it serves narrow clinical populations in specialized urinary tract cancer settings, so care is built around exact diagnosis, procedure timing, and symptom relief. That focused model supports outcome tracking and closer follow-up for patients who often have few options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNarrow populations, tailored care\u003c\/li\u003e\n\u003cli\u003eSpecialized urinary tract cancer settings\u003c\/li\u003e\n\u003cli\u003eOutcome-led patient support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUroGen’s Specialist Network Drives 2025 Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. manages customer relationships through a tight specialist network: urologists, oncologists, and procedure centers that drive diagnosis, prescribing, and use. In 2025, its 2 marketed therapies and 3 named partner ties made medical affairs updates, partner governance, and patient support the core link to adoption and repeat use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed therapies\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eSupports specialist follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed partner ties\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003eRequires active governance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eChannels\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist urology practices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialist urology practices are UroGen Pharma Ltd.'s key gatekeepers for urinary tract disease care, since urologists make the treatment call for most patients. This channel matters for Jelmyto, the first FDA-approved chemoablation therapy for low-grade upper tract urothelial cancer, a niche that represents roughly 5% to 10% of urothelial cancers, and for future launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology treatment centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology treatment centers are UroGen Pharma Ltd.’s core channel because high-grade and non-muscle invasive bladder cancers are treated in specialty cancer sites. In the U.S., bladder cancer still drives about 83,190 new cases a year and 16,840 deaths in 2024, so major centers like MD Anderson matter for evidence adoption, protocol use, and institutional access to therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. uses clinical trial networks as a core channel for UGN-102, which is in Phase III studies. Trial centers and investigators drive patient enrollment and generate the data needed for regulatory review, while also building awareness among urology specialists for future adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner commercialization pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllergan-related rights can widen UroGen Pharma Ltd. commercialization reach by tapping an established urology sales base, while Agenus partnership activity gives it external development and production routes that can speed scale-up without adding full in-house capacity. Partner channels lower launch friction and broaden market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAllergan rights expand reach\u003c\/li\u003e\n\u003cli\u003eAgenus supports development and production\u003c\/li\u003e\n\u003cli\u003ePartners widen market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCompany commercial organization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. sells Jelmyto directly through its own commercial team, so the company controls pricing, field force activity, and physician outreach. That internal execution is the main engine for current revenue, because uptake depends on educating urologists and driving adoption in the office and hospital channel.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect-to-physician sales model\u003c\/li\u003e\n\u003cli\u003eInternal education drives uptake\u003c\/li\u003e\n\u003cli\u003eJelmyto is the core revenue source\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHow UroGen Reaches a Narrow but Valuable Cancer Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. reaches patients mainly through urology specialists, oncology centers, and trial networks, with Jelmyto sold by its own field team and partner channels extending access. This mix fits a niche market: low-grade upper tract urothelial cancer is about 5% to 10% of urothelial cancers, while U.S. bladder cancer cases were 83,190 in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrology practices\u003c\/td\u003e\n\u003ctd\u003ePrimary prescribing gatekeeper\u003c\/td\u003e\n\u003ctd\u003e5% to 10% niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology centers\u003c\/td\u003e\n\u003ctd\u003eSpecialty access\u003c\/td\u003e\n\u003ctd\u003e83,190 U.S. cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials and partners\u003c\/td\u003e\n\u003ctd\u003eUGN-102 and scale-up\u003c\/td\u003e\n\u003ctd\u003ePhase III\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Segments\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-grade UTUC patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUGN-102 targets low-grade upper tract urothelial carcinoma, a rare, defined urinary tract cancer segment that is UroGen Pharma Ltd.’s primary clinical focus. UTUC accounts for about 5% to 10% of urothelial cancers, and low-grade disease is often managed with kidney-sparing therapy, making these patients a clear need-based customer segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-grade NMIBC patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd.’s UGN-102 targets low-grade NMIBC, a niche that makes up about 75% of bladder cancer cases and needs repeated, specialist bladder treatment. In the phase 3 ENVISION study, UGN-102 showed a 79.6% complete response rate at 3 months, making this segment central to UroGen Pharma Ltd.’s late-stage pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-grade NMIBC patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-grade NMIBC is UroGen Pharma Ltd.’s higher-risk target, and UGN-301 is being built for this more advanced segment. Non-muscle invasive bladder cancer makes up about 75% of new bladder cancer cases, while high-grade disease has a much higher chance of recurrence and progression, so the need for non-surgical options is real.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUrologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUrologists are UroGen Pharma Ltd.'s core prescribers because they diagnose urinary tract disease, perform office procedures, and manage the full patient pathway. In practice, this means UroGen must win over a small, specialist audience that directly drives treatment choice and repeat use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKey prescribers for urinary tract care\u003c\/li\u003e\n\u003cli\u003eGuide diagnosis and procedures\u003c\/li\u003e\n\u003cli\u003eControl patient referral and treatment flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology centers and hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncology centers and hospitals are core institutional customers for UroGen Pharma Ltd. Specialty cancer centers run trials, adopt new therapies fast, and deliver treatment at scale; MD Anderson, with more than 1.6 million patient visits a year, shows how major centers shape uptake. These buyers also drive referral flow and protocol use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial sites speed evidence generation\u003c\/li\u003e\n\u003cli\u003eMajor centers influence adoption\u003c\/li\u003e\n\u003cli\u003eHospitals support repeat treatment delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUroGen Targets Rare Urothelial Cancer Niches With Strong Clinical Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. serves a narrow, specialist customer base: patients with low-grade UTUC, low-grade and high-grade NMIBC, plus the urologists, cancer centers, and hospitals that diagnose and treat them. This matters because urothelial cancer is rare and specialist-led, with UTUC at about 5% to 10% of urothelial cancers and NMIBC at about 75% of new bladder cancer cases.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLow-grade UTUC\u003c\/td\u003e\n\u003ctd\u003e5% to 10% of urothelial cancers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNMIBC\u003c\/td\u003e\n\u003ctd\u003eAbout 75% of new bladder cancers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUGN-102\u003c\/td\u003e\n\u003ctd\u003e79.6% CR at 3 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCost Structure\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and development expense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2024, UroGen Pharma Ltd. spent about $106 million on research and development, funding discovery, preclinical work, and platform development. This is a structural cost because the pipeline depends on steady R\u0026amp;D outlays to keep new programs moving forward.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III clinical trial costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUGN-102 Phase III work needs patient recruitment, site monitoring, data review, and final analysis, so it burns cash fast; UroGen Pharma Ltd. has said clinical development is a major use of capital. Late-stage oncology and urology trials often run for years and can cost tens of millions of dollars before any approval decision.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd.'s manufacturing and supply costs are driven by Jelmyto production, batch quality control, and regulated supply-chain execution. In FY2025, the company also kept spending on other formulations in development, while third-party manufacturing partners can add fixed fees and per-batch costs, raising unit cost when volumes are still limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSales and commercialization expense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSales and commercialization expense covers the commercial team, physician engagement, and launch prep for pipeline assets. For UroGen Pharma Ltd., this spend supports Jelmyto adoption and revenue growth, but it also lifts SG\u0026amp;A as the company builds its market reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCommercial staff drive Jelmyto uptake.\u003c\/li\u003e\n\u003cli\u003ePhysician outreach supports prescribing.\u003c\/li\u003e\n\u003cli\u003ePipeline launch prep raises selling costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing and collaboration costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. carries licensing and collaboration costs tied to its agreements with Allergan, Agenus, and MD Anderson, which can mean upfront fees, milestone payments, shared development spend, and contract oversight. In 2025, these partnership obligations remained a core part of the Company Name’s cost base, alongside ongoing R\u0026amp;D spending.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eFees and milestones can lift cash costs.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eShared development spend adds variability.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eContract management is a recurring overhead.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUroGen’s R\u0026amp;D-Heavy Cost Base Still Weighs on Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUroGen Pharma Ltd.’s cost structure stays R\u0026amp;D-heavy: FY2024 research and development was about $106 million, while FY2025 still carried high clinical, manufacturing, and launch spend to support Jelmyto and UGN-102. Shared-deal costs also matter, with licensing, milestones, and partner oversight adding recurring fixed and variable charges.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost driver\u003c\/th\u003e\n\u003cth\u003eLatest cited data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$106 million in FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trials\u003c\/td\u003e\n\u003ctd\u003eMajor capital use in FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eBatch and QC costs rise with low volumes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eSG\u0026amp;A rises with Jelmyto uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRevenue Streams\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJelmyto product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJelmyto is UroGen Pharma Ltd.'s only marketed product, so its sales are the company’s sole commercial revenue stream. In 2025, product sales from Jelmyto continued to anchor the operating model, making uptake, refills, and payer access the key drivers of revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture UGN-102 commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUGN-102 is in Phase III, so it is the clearest near-term pipeline driver for UroGen Pharma Ltd. If approved, it could become a major future revenue source in low-grade UTUC and low-grade NMIBC, two niches with limited treatment options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture UGN-301 commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUGN-301 could add a second oncology revenue stream for UroGen Pharma Ltd if it wins approval in high-grade NMIBC, a market with about 83,000 new U.S. bladder cancer cases a year and a high recurrence burden. That would extend earnings beyond UroGen Pharma Ltd's current product base and improve long-term growth potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing income from Allergan agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Allergan agreement covers 2 product families, RTGel and clostridial toxin products, so UroGen Pharma Ltd can earn licensing income through upfront, milestone, and commercialization-linked payments. This is a partner-based stream, where revenue rises as Allergan advances rights and sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 product families in scope\u003c\/li\u003e\n\u003cli\u003ePayments tied to rights\u003c\/li\u003e\n\u003cli\u003eCommercialization-linked income\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCollaboration-related payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUroGen Pharma Ltd. uses collaboration-related payments to help fund research and development, so partner cash can support pipeline progress before product sales scale. The Agenus and MD Anderson relationships add collaboration value by sharing development cost and risk, and this mattered in UroGen Pharma Ltd.’s 2025 funding mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner payments help finance R\u0026amp;D.\u003c\/li\u003e\n\u003cli\u003eAgenus adds collaboration value.\u003c\/li\u003e\n\u003cli\u003eMD Anderson supports pipeline work.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJelmyto Leads UroGen’s Revenue, With Pipeline Upside Ahead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJelmyto was UroGen Pharma Ltd.'s only marketed product in 2025, so product sales were the main revenue stream. Near term, UGN-102 and UGN-301 could add new sales if approved, while Allergan, Agenus, and MD Anderson support partner-based cash through milestones and collaboration payments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJelmyto sales\u003c\/td\u003e\n\u003ctd\u003eOnly marketed product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUGN-102\u003c\/td\u003e\n\u003ctd\u003ePhase III pipeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUGN-301\u003c\/td\u003e\n\u003ctd\u003eTargets 83,000 U.S. cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllergan\u003c\/td\u003e\n\u003ctd\u003e2 product families\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235021988105,"sku":"urgn-business-model-canvas","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/urgn-business-model.webp?v=1785734844","url":"https:\/\/dcfanalyst.com\/products\/urgn-business-model-canvas","provider":"DCF Analyst","version":"1.0","type":"link"}